Menu
Recruiting NCT06516653

Post Market Study for VasQ, an External Support Implant for Arteriovenous Fistula

No phase Interventional End Stage Renal Disease

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: VasQ, Arteriovenous fistula creation for dialysis vascular access.
Who it may be relevant to
Registry conditions: End Stage Renal Disease. Basic parameters: 18 years — 80 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Postmarket Surveillance, Prospective, Multicenter, Randomized, Controlled Study Evaluating the Performance of VasQ for Its Intended Use.

Overview

VasQ is an external support implant for arteriovenous fistulas created for dialysis access. This is a postmarket surveillance, prospective, multi-center, randomized, controlled, open label trial enrolling 300 patients randomized into two study arms: * Treatment arm: End to side fistula supported with VasQ * Control: Standard of care end to side fistula

Detailed description

Structure

This is a postmarket surveillance, prospective, multi-center, randomized, controlled, open label trial enrolling 300 patients randomized into two study arms:

* Treatment arm: End to side fistula supported with VasQ * Control: Standard of care end to side fistula

Duration The primary endpoint is defined at 6 month post index procedure of fistula creation. Patients will be further followed up to 12 months post index procedure.

Main study question What is the magnitude of benefit of the VasQ device with regard to time to achieving a clinically functional AVF as compared to a comparable contemporary standard of care cohort?

Interventions

  • Device VasQ
    External support implant for the arteriovenous fistula
  • Procedure Arteriovenous fistula creation for dialysis vascular access
    End to side fistula creation in the arm for dialysis vascular access

Primary outcome measures

  • Fistula functional success [Time frame: 6 months]

Eligibility criteria

Inclusion criteria

  • Patients who are candidates for the creation of a new radiocephalic or brachiocephalic end-to-side surgical AV fistula for dialysis access (per VasQ IFU and investigator clinical judgment) and consent to take part in the study.
  • Male and non-pregnant female participants.
  • Age 18-80 years
  • Patients willing and able (physically and geographically) to attend follow up visits over a period of 12 months.

Exclusion criteria

  • Index procedure being a revision surgery of an existing fistula.
  • Significantly stenotic target vein on the side of surgery (≥50%) as diagnosed on preoperative ultrasound. (Scan should include the full length of the expected fistula outflow, starting at the planned anastomosis site)
  • Unusual anatomy or vessel dimensions (observed on pre-operative ultrasound or intraoperatively) and which preclude adequate fit of the VasQ.
  • Known central venous stenosis or obstruction on the side of surgery.
  • Pre-existing stents or stent grafts in the access circuit.
  • Planned subsequent fistula superficialization procedure.
  • Known coagulation disorder.
  • Known allergy to nitinol.
  • Expected kidney transplant within 12 months of enrollment.
  • Inability to give consent and/or comply with the study follow up schedule.
  • Insufficient or borderline life expectancy to allow for completion of study procedures and follow-up (12 Months).
  • Participation in another interventional study that in the judgment of the investigator could confound study results.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Prevention

Study locations

United States · 9 centers
  • Fresenius Vascular Care Long Beach — Long Beach
  • Sarasota Memorial Hospital — Sarasota
  • Grady Memorial Hospital — Atlanta
  • Brigham and Women's Hospital — Boston
  • Greenwood Leflore Hospital — Greenwood
  • Azura Surgery Center Las Vegas — Las Vegas
  • Fresenius Vascular Care Columbia — Columbia
  • Houston Methodist Hospital — Houston
  • … and 1 more center

Identifiers

NCT: NCT06516653 · CD0261

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗